KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Revenue: 2019-2024

Historic Revenue for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Dec 2024 value amounting to $58.8 million.

  • Recursion Pharmaceuticals' Revenue fell 80.16% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.7 million, marking a year-over-year decrease of 32.98%. This contributed to the annual value of $58.8 million for FY2024, which is 32.00% up from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Revenue of $58.8 million as of FY2024, which was up 32.00% from $44.6 million recorded in FY2023.
  • Over the past 5 years, Recursion Pharmaceuticals' Revenue peaked at $58.8 million during FY2024, and registered a low of $4.0 million during FY2020.
  • For the 3-year period, Recursion Pharmaceuticals' Revenue averaged around $47.8 million, with its median value being $44.6 million (2023).
  • Data for Recursion Pharmaceuticals' Revenue shows a peak YoY spiked of 291.46% (in 2022) over the last 5 years.
  • Recursion Pharmaceuticals' Revenue (Yearly) stood at $4.0 million in 2020, then spiked by 156.89% to $10.2 million in 2021, then skyrocketed by 291.46% to $39.8 million in 2022, then grew by 11.88% to $44.6 million in 2023, then skyrocketed by 32.00% to $58.8 million in 2024.